Guardant Health (NASDAQ:GH) CEO Amirali Talasaz Sells 116,972 Shares

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 116,972 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $150.79, for a total transaction of $17,638,207.88. Following the completion of the transaction, the chief executive officer owned 1,881,336 shares in the company, valued at $283,686,655.44. This represents a 5.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amirali Talasaz also recently made the following trade(s):

• On Monday, June 29th, Amirali Talasaz sold 143,028 shares of Guardant Health stock. The stock was sold at an average price of $151.54, for a total value of $21,674,463.12.
• On Wednesday, May 20th, Amirali Talasaz sold 210,000 shares of Guardant Health stock. The stock was sold at an average price of $109.89, for a total value of $23,076,900.00.
• On Tuesday, May 12th, Amirali Talasaz sold 50,000 shares of Guardant Health stock. The shares were sold at an average price of $100.32, for a total transaction of $5,016,000.00.

Guardant Health Price Performance

Shares of NASDAQ GH opened at $150.03 on Wednesday. Guardant Health, Inc. has a 1 year low of $40.35 and a 1 year high of $153.95. The company’s 50-day moving average is $115.18 and its 200 day moving average is $104.71. The stock has a market capitalization of $19.89 billion, a P/E ratio of -44.26 and a beta of 1.61.

Institutional Trading of Guardant Health

Large investors have recently added to or reduced their stakes in the business. V Square Quantitative Management LLC bought a new stake in shares of Guardant Health during the 4th quarter valued at $27,000. Chesapeake Asset Management LLC bought a new position in Guardant Health in the 4th quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Guardant Health in the 4th quarter worth $31,000. Elyxium Wealth LLC purchased a new position in Guardant Health during the fourth quarter valued at $35,000. Finally, Parallel Advisors LLC lifted its position in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after purchasing an additional 219 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on GH. Sanford C. Bernstein started coverage on Guardant Health in a research note on Friday, June 26th. They set an “outperform” rating and a $175.00 price objective for the company. The Goldman Sachs Group initiated coverage on Guardant Health in a report on Friday, June 5th. They set a “buy” rating and a $165.00 price target for the company. Guggenheim lifted their price target on Guardant Health from $135.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday. Evercore upgraded shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price target on the stock in a research note on Tuesday, June 2nd. Finally, Barclays increased their price objective on shares of Guardant Health from $120.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Guardant Health currently has a consensus rating of “Buy” and an average target price of $144.82.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.